Dual role of endothelial Myct1 in tumor angiogenesis and tumor immunity
- 3 March 2021
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (583)
- https://doi.org/10.1126/scitranslmed.abb6731
Abstract
The cross-talk between angiogenesis and immunity within the tumor microenvironment (TME) is critical for tumor prognosis. While pro-angiogenic and immunosuppressive TME promote tumor growth, anti-angiogenic and immune stimulatory TME inhibit tumor progression. Therefore, there is a great interest in achieving vascular normalization to improve drug delivery and enhance antitumor immunity. However, anti–vascular endothelial growth factor (VEGF) mechanisms to normalize tumor vessels have offered limited therapeutic efficacies for patients with cancer. Here, we report that Myct1, a direct target of ETV2, was nearly exclusively expressed in endothelial cells. In preclinical mouse tumor models, Myct1 deficiency reduced angiogenesis, enhanced high endothelial venule formation, and promoted antitumor immunity, leading to restricted tumor progression. Analysis of The Cancer Genome Atlas (TCGA) datasets revealed a significant (P < 0.05) correlation between MYCT1 expression, angiogenesis, and antitumor immunity in human cancers, as suggested by decreased FOXP3 expression and increased antitumor macrophages in patients with low MYCT1 expression. Mechanistically, MYCT1 interacted with tight junction protein Zona Occludens 1 and regulated Rho GTPase-mediated actin cytoskeleton dynamics, thereby promoting endothelial motility in the angiogenic environment. Myct1-deficient endothelial cells facilitated trans-endothelial migration of cytotoxic T lymphocytes and polarization of M1 macrophages. Myct1 targeting combined with anti-PD1 treatment significantly (P < 0.05) increased complete tumor regression and long-term survival in anti-PD1–responsive and –refractory tumor models in mice. Our data collectively support a critical role for Myct1 in controlling tumor angiogenesis and reprogramming tumor immunity. Myct1-targeted vascular control, in combination with immunotherapy, may become an exciting therapeutic strategy.Keywords
Funding Information
- National Institutes of Health (R01HL149954)
- National Institutes of Health (R01HL55337)
- National Institutes of Health (R01HL119291)
- National Institutes of Health (K08HL135400)
- National Institutes of Health (00060337)
- NIH Office of the Director (R01HL149954)
- NIH Office of the Director (R01HL55337)
- Children’s Healthcare of Atlanta (00060337)
- NIH Office of the Director (R01HL119291)
- NIH Office of the Director (K08HL135400)
This publication has 79 references indexed in Scilit:
- A Core Human Primary Tumor Angiogenesis Signature Identifies the Endothelial Orphan Receptor ELTD1 as a Key Regulator of AngiogenesisCancer Cell, 2013
- The 'invisible hand': regulation of RHO GTPases by RHOGDIsNature Reviews Molecular Cell Biology, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- The Immunological Genome Project: networks of gene expression in immune cellsNature Immunology, 2008
- Modes of resistance to anti-angiogenic therapyNature Reviews Cancer, 2008
- ER71 Acts Downstream of BMP, Notch, and Wnt Signaling in Blood and Vessel Progenitor SpecificationCell Stem Cell, 2008
- Autocrine VEGF Signaling Is Required for Vascular HomeostasisCell, 2007
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- Tumor Angiogenesis: Therapeutic ImplicationsThe New England Journal of Medicine, 1971